Program Description
Relapsed or refractory non-Hodgkin lymphoma, including diffuse large B-cell lymphoma or follicular lymphoma, presents significant therapeutic challenges as patients progress through successive lines of treatment. The rapid expansion of bispecific antibodies (BsAbs) has reshaped the treatment landscape, making it increasingly challenging to distinguish among available agents and guide treatment selection and sequencing as clinical evidence evolves. Beyond treatment selection, BsAb–associated toxicities, particularly cytokine release syndrome and immune effector cell–associated neurotoxicity syndrome, require early recognition and timely intervention, especially as treatment shifts from monitored inpatient settings to outpatient and community practice. This shift presents additional operational challenges involving care coordination, monitoring protocols, and escalation pathways, reinforcing the need for practical pharmacist education in toxicity management, patient counseling, and safe treatment delivery. This activity will examine comparative clinical evidence for BsAbs, strategies for toxicity recognition and escalation, and practical approaches to outpatient implementation. By focusing on real-world challenges, oncology pharmacists will gain strategies to guide individualized treatment decisions and support safe BsAb delivery across practice settings.
Target audience: Oncology Pharmacist
Type of activity: Application
Release date: December 1, 2026
Expiration date: February 1, 2026
Time to complete activity: 1 hour
Learner level: Foundational, Intermediate
Fee: Free
Educational Objectives
At the completion of this activity, pharmacists will be able to:
- Distinguish the comparative clinical evidence for bispecific antibodies for patients with relapsed/refractory non-Hodgkin lymphoma to inform individualized treatment selection.
- Apply toxicity recognition and escalation strategies for patients with relapsed/refractory non-Hodgkin lymphoma receiving bispecific antibody therapy to support safe outpatient management.
- Select operational strategies for patients with relapsed/refractory non-Hodgkin lymphoma receiving bispecific antibody therapy to inform safe outpatient implementation within their practice setting.
Samantha Maples, PharmD, BCOP
Clinical Pharmacy Specialist Supervisor
Hematology and Cellular Therapy
Allegheny Health Network
Pittsburgh, PA
Accreditation Information
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This application-based activity is approved for 1.0 contact hour (0.1 CEU) under the ACPE universal activity number [UAN pending]. The activity is available for CE credit through February 1, 2026.
Obtaining Credit
All participants who attended the live virtual broadcast need to log on to their Pharmacy Times Continuing Education™ account on www.pharmacytimes.org to complete an online evaluation form and request their credit. Instructions on receiving credit will be provided the day of the event.
Instructions for Completing the Activity and Receiving CPE Credit
To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.
Disclosures
Samantha Maples, PharmD, BCOP, has the following relevant financial relationships with ineligible companies: Consultant: Bristol Myers Squibb, Janssen.
Pharmacy Times Continuing Education™ Planning Staff: Jim Palatine, RPh, MBA; Alyssa Bradshaw, PharmD, BCOP; Emily Tyler; and Brianna Winters have no financial relationships with ineligible companies to disclose.
All of the relevant financial relationships listed for these individuals have been mitigated.
At least 1 anonymous peer reviewer has been used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with ineligible companies to disclose.
Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.
For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms